Tuesday, November 17, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
How to earnPaparazzi InkHolder perksLeaderboardAssignmentsContestsLeagueCity
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsCity LeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundToken utilityRobinhood Chain launchesRobinhood Chain projectsPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 54

FDA Greenlights First Treatment for Deadly Sanfilippo Syndrome

The FDA has approved the first-ever treatment for Sanfilippo syndrome Type A, a rare genetic killer targeting the central nervous system. This gene therapy offers hope for stabilization and prevention, though families are now focused on tackling high costs and access hurdles.

By the Paparazzi desk November 16, 2026 · 4:00 PM · wdsu.com · 0 views
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: wdsu.com.
  • The source published it on Nov 16, 2026 at 4:00 PM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

>The FDA has officially given the green light for the first-ever treatment for children battling Sanfilippo syndrome Type A. This gene therapy marks a major breakthrough for those fighting this rare and deadly genetic disease.

>The treatment delivers a healthy, functional copy of a gene, allowing the body to produce the enzyme it is genetically deficient in. Cure Sanfilippo Foundation founders noted that the therapy is specifically designed for prevention and stabilization, not reversal.

Sponsored

>Access, however, is complicated. For the treatment to be provided, a child must not have been exposed to the viral vector and must not have antibodies above a certain level. Coverage for the nearly $4 million treatment cost presents another major hurdle for families.

>Glenn and Cara O'Neill, founders of the Cure Sanfilippo Foundation, are pushing for advanced research to develop treatments for other types of Sanfilippo syndrome, including Types B, C, and D.

>Cara Bergeron, mother of Asher Bergeron, shared that the hope is simply to extend his life so his family can enjoy his smile for a little longer.

entities]: [

TopicsFDA · Sanfilippo syndrome · Cure Sanfilippo Foundation · Asher Bergeron · Cara Bergeron · Glenn O'Neill · Cara O'Neill

Share

Source: wdsu.com

Written by AI from verified reporting.

More stories

  • Health & science 32 minutes ago · healthandme.com · 0 views
    Europe approves Revolution Medicines' RAS-blocking pancreatic cancer pill
  • Health & science 2 hours ago · finance.yahoo.com · 0 views
    Novartis' Cosentyx wins FDA nod as first anti-IL-17 biologic for PMR
  • Health & science 4 hours ago · casrai.org · 0 views
    FDA greenlights giredestrant-everolimus duo for ESR1-mutated breast cancer
  • Health & science 5 hours ago · nbcnews.com · Caught by @nina.anggraini29 · 0 views
    Measles Is Endemic Again as the U.S. Loses Its Elimination Status
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.